Molbio Diagnostics Plans ₹200 Crore IPO Amid Global Expansion

Molbio Diagnostics, a key player in the molecular diagnostics sector, is gearing up to launch an initial public offering (IPO) aimed at raising ₹200 crore for capital expenditures. This financial move is part of a broader strategy to bolster its manufacturing capabilities and expand its global market presence. Additionally, the company plans to reduce its promoter stake by generating ₹740 crore through an offer for sale, which will decrease the promoter group's holding from 46.6% to 43%.

Global Reach and Revenue Streams

With six manufacturing facilities across India, Molbio Diagnostics serves clients in over 90 countries. The company's client base includes government health programs, diagnostic labs, hospitals, and international healthcare organizations. The firm's growth has been significantly driven by its tuberculosis diagnostic test kits, which account for a substantial portion of its revenue. In fact, nearly 74% of its revenue stems from the sale of test kits, with 70% coming specifically from tuberculosis diagnostics.

Financial Performance and Market Position

Molbio Diagnostics has demonstrated robust financial growth over recent years. Between the fiscal years 2024 and 2026, revenue from operations increased by 31.5% annually, reaching ₹1,445.7 crore. Net profit also saw a significant rise of 40.2% annually, amounting to ₹164.1 crore. The company's EBITDA grew by 33.2% to ₹328.2 crore, with the EBITDA margin improving from 22% in FY24 to 22.6% in FY26. In FY26 alone, revenue jumped by 41.7%, while EBITDA and net profit grew by 27.9% and 18.4% year-on-year, respectively.

Valuation and Investor Considerations

The IPO positions Molbio Diagnostics at a price-earnings (P/E) multiple of up to 57, which is competitive when compared to other healthcare diagnostics and medical device companies like Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, whose P/E multiples range from 54 to 81. The firm's focus on innovation, particularly its 'Truenat' platform—an advanced diagnostic system designed for resource-limited settings—further strengthens its market position.

Incorporated in 2000, Molbio Diagnostics has consistently focused on research, development, and manufacturing of diagnostic solutions for both infectious and non-communicable diseases. Government and international aid agencies contribute significantly to its revenue, accounting for over 80%. Given its strong financial performance and strategic initiatives, the IPO presents a potentially attractive opportunity for investors with a high-risk appetite looking for long-term growth.